衞生署藥物辦公室
藥物資訊及進出口管制科
香港九龍觀塘巧明街 100 號
Landmark East 友邦九龍大樓
20 樓 2002-05 室

DEPARTMENT OF HEALTH
DRUG OFFICE
DRUG INFORMATION AND
IMPORT/EXPORT CONTROL DIVISION
Suites 2002-05, 20/F, AIA Kowloon Tower,
Landmark East, 100 How Ming Street,
Kwun Tong, Kowloon, Hong Kong

電話號碼 Tel. No.: (852) 3974 4175
詢問處 Enquiries (852) 3974 4175
傳真號碼 Faxline No.: (852) 2803 4962
本署檔號 OUR REF.:

(來函請敘明此檔案號碼) DH DO DIMC/7-30/1
(IN REPLY PLEASE QUOTE THIS FILE REF.)

4 Sep 2025

Dear Healthcare Professionals,

Lipidem® 200mg/ml Emulsion for Infusion (10 x 500 ml): Important information on subvisual agglomerates and the need to use an infusion filter for fat emulsions

Your attention is drawn to the following Singapore Health Sciences Authority's (HSA) announcement that a Dear Healthcare Professional Letter has been issued by B. Braun Singapore Pte Ltd to inform healthcare professionals that subvisual droplet-like structures of emulsion components were detected in Lipidem® 200mg/ml Emulsion for Infusion (10 x 500 ml). The earliest time of the subvisual droplet-like structures of emulsion components detection was 18 months. At higher temperatures, this effect may occur earlier. Intravenous administration of the droplet-like structures can lead to adverse events such as embolism in the capillary tissue of the lungs. Healthcare professionals are advised to use the lipid emulsion filter with a pore size of 1.2 µm (Intrapur® Lipid 1.2µm infusion filter) with Lipidem® 200mg/ml Emulsion for Infusion until further notice.

Please refer to the following website in HSA for details:
https://www.hsa.gov.sg/announcements/dear-healthcare-professional-letter/lipidem--200mg-ml-emulsion-for-infusion-(10-x-500-ml)--important-information-on-subvisual-agglomerates-and-the-need-to-use-an-infusion-filter-for-fat-emulsions

In Hong Kong, Lipidem Emulsion For Infusion (HK-58945) is a pharmaceutical product registered by B. Braun Medical (HK) Ltd. It is a prescription-only medicine indicated for supply of energy, including a readily utilisable lipid component (medium-chain triglycerides) and essential omega-6 fatty acids and omega-3 fatty acids, as part of parenteral nutrition when oral or enteral nutrition is impossible, insufficient or contraindicated. So far, the Department of Health (DH) has not received any case of adverse drug reaction with regard to Lipidem. The DH will remain vigilant on safety update of the drug issued by other overseas drug regulatory authorities.

Please note that this letter serves as a means for the DH to communicate important new safety information about registered pharmaceutical products with healthcare professionals in Hong Kong and is not intended to serve as guidelines or to replace professional clinical judgement. Healthcare professionals are advised to balance the risk of possible adverse effects against the benefit of treatment.

Please report any adverse events caused by drugs to the Clinical Trials and Pharmacovigilance Unit of the DH (tel. no.: 2319 2920, fax: 2319 6319 or email: adr@dh.gov.hk). For details, please refer to the website at Drug Office under "ADR Reporting": http://www.drugoffice.gov.hk/adr.html. You may wish to visit the Drug Office's website for subscription and browsing of "Drug News" which is a monthly digest of drug safety news and information issued by Drug Office.

Yours faithfully,

(Vincent CHIANG)
for Assistant Director (Drug)